Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000)
Top Cited Papers
- 17 December 2009
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 24 (2), 320-334
- https://doi.org/10.1038/leu.2009.253
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With DexrazoxaneJournal of Clinical Oncology, 2008
- BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemiaBlood, 2008
- Neuropsychological Outcomes From a Randomized Trial of Triple Intrathecal Chemotherapy Compared With 18 Gy Cranial Radiation As CNS Treatment in Acute Lymphoblastic Leukemia: Findings From Dana-Farber Cancer Institute ALL Consortium Protocol 95-01Journal of Clinical Oncology, 2007
- Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01Blood, 2007
- Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic LeukemiaJama-Journal Of The American Medical Association, 2007
- Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemiaBlood, 2006
- Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01Blood, 2006
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988
- Four-Agent Induction and Intensive Asparaginase Therapy for Treatment of Childhood Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958